Actineer Inc. is a joint venture focused on the industrial scale production of Actinium-225, a medical isotope used in targeted alpha therapy for cancer treatment.

Actineer

Actineer, Inc. | 447 followers on LinkedIn. Actineer™ Inc. is a joint venture company between Canadian Nuclear Laboratories (CNL) and ITM Isotope Technologies Munich SE (ITM) dedicated to advancing Ac-225 technologies, quickly securing supply, and producing industrial-scale quantities of this valuable, rare medical radioisotope for the treatment of cancer.  Founded in October 2023, Actineer™ Inc. together with its strong supply chain collaborators will progress Ac-225 development, production and processing technologies to establish short-term production capabilities that will significantly boost international supplies, while working long-term towards the construction of a new Actinium Production Facility (APF) in Canada. The joint venture’s mission is to fulfil the unmet global manufacturing and production needs of this coveted radioisotope with significant potential in the fight against cancer.

Director Business and Operations - Actineer Inc.

Dr. Andreas Benischke

Actineer, Inc.

Actineer Advances Actinium-225 Production! We are proud to announce that Actineer, the joint venture between ITM Isotope Technologies Munich SE and Canadian Nuclear Laboratories (CNL), has successfully completed the cyclotron irradiation of Radium-226 (Ra-226), marking a significant step forward in the production of #Actinium -225 ( #Ac -225). An important achievement to support the development of #TargetedAlphaTherapy ( #TAT ) and provide cancer patients with new treatment options. For more details, check out our announcement: https://lnkd.in/dgB9_YSX

Exciting News! 🚀 Our new corporate website is LIVE! ✨ Check out www.actineer.com and explore the potential of Actinium-225 for next-generation #radiopharmaceuticals in cancer treatment. This new website provides valuable information about Actinium-225 as a medical radioisotope and the unique synergy between Canadian Nuclear Laboratories and ITM Isotope Technologies Munich SE in building this joint venture with its cross-functional supply chain from manufacturing to sales & distribution. #WebsiteLaunch #Actinium

Learn more about #Actinium225 as a potential weapon in the fight against cancer at the #webinar hosted by the Canadian Nuclear Isotope Council and 𝗔𝗰𝘁𝗶𝗻𝗲𝗲𝗿 on April 11, 2024. 💡 The hour-long event will highlight how industry is revolutionizing the production of emerging medical #isotopes like Ac-225, how Canadian Nuclear Laboratories and ITM Isotope Technologies Munich SE 's new joint venture Actineer, Inc. is working to produce Ac-225 at a commercial scale, and how Ac-225 and Targeted Alpha Therapy (TAT) offers significant benefits to cancer patients. ⚕️ Moderated by 𝗔𝗻𝗱𝗿𝗲𝘄 𝗧𝗵𝗶𝗲𝗹𝗲 , Executive Director of Canadian Nuclear Isotope Council, the webinar will platform: 👉 Carolina Aguiar Ferreira - Assistant Professor of Radiology, Pharmacology & Toxicology and Biomedical Engineering at Michigan State University 👉 Mike Sathekge - Head of Nuclear Medicine, University of Pretoria and Steve Biko Academic Hospital, South Africa 👉 Ram Mullur - President of Actineer, Inc. To register for this webinar please click the button below. #radiopharmaceuticals #PrecisionOncology

We are proud to be a member of the Canadian Nuclear Isotope Council and are looking forward to this collaboration. Read the full press release here: https://lnkd.in/gTAJ4e5Z #actinium #radiopharma #radiopharmaceutical #oncology

ACTI

COM:ACTINEER

Actineer

Financials Not Available